阿帕替尼联合替吉奥对晚期胃癌患者血清肿瘤标志物水平的影响

Effects of Apatinib Combined with Tegafur on the Levels of Serum Tumor Markers in Patients with Advanced Gastric Cancer

目的探讨阿帕替尼联合替吉奥对晚期胃癌患者血清肿瘤标志物水平的影响。方法选取2016年3月至2019年3月抚州市第一人民医院收治的晚期胃癌患者60例作为研究对象,按随机数字表法分为观察组与对照组,各30例。对照组接受替吉奥治疗,观察组则加用阿帕替尼治疗,比较两组近期疗效、肿瘤标志物[糖类抗原199(CA199)、癌胚抗原(CEA)]及不良反应发生情况。结果观察组疾病控制率(86.67%)高于对照组(63.33%),差异有统计学意义(P<0.05);治疗后观察组CA199(11.64±5.19)U/ml、CEA(2.64±0.53)ng/ml,低于对照组的(21.97±5.83)U/ml、(3.18±0.76)ng/ml,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论晚期胃癌患者接受阿帕替尼、替吉奥联合治疗是安全可行的,有利于降低血清肿瘤标志物水平,提升抗肿瘤效果,且不良反应并未增加。

Objective To explore the effects of Apatinib combined with Tegafur on the levels of serum tumor markers in patients with advanced gastric cancer. Methods From March 2016 to March 2019, 60 patients with advanced gastric cancer admitted to the First people’s Hospital of Fuzhou City were selected as the study objects, and were divided into observation group and control group according to the random number table method, with 30 cases each. The control group was treated with Tegafur, while the observation group was treated with apatinib. The short-term efficacy, tumor markers [carbohydrate antigen 199(CA199), carcinoembryonic antigen(CEA)]and adverse reactions were compared between the 2 groups. Results The disease control rate(86.67%) in the observation group was higher than that in the control group(63.33%)(P<0.05). After treatment, CA199(11.64±5.19) U/ml, and CEA(2.64±0.53) Ng/ml in the observation group, were lower than the control group, which were(21.97±5.83) U/ml,(3.18±0.76) ng/ml(P<0.05). There was no difference in the incidence of adverse reactions between the 2 groups(P>0.05). Conclusion The combination of Apatinib and Tegafur in patients with advanced gastric cancer is safe and feasible. It can reduce the level of serum tumor markers and improve the anti-tumor effects, and the adverse reactions have not increased.